Author archives

Petre I. CALISTRU

Latest posts by Petre I. CALISTRU (see all)

    Articles signed on MÆDICA, JCM:

    Primary Hepatic Marginal Zone Lymphoma in a Patient with Chronic Hepatitis C

    SELECT ISSUE

    MÆDICA - a Journal of Clinical Medicine | Vol. 11, nr. 3, 2016
    ISSN 1841-9038  |  e-ISSN 2069-6116
    ISSN-L 1841-9038
    CNCSIS - CMR - B+

    HIGHLIGHTS

    Plagiatul – in actualitate

    Tema plagiatului este tot mai mult discutata in ultima vreme. Aparitia unor programe performante de cautare si identificare a similitudinilor intre texte [...]

    Committe on Publication Ethics

    A forum for responsible and ethical research publishing – Code of Conduct and Best Practice Guidelines for Journal Editors.

    Members Area


    Primary Hepatic Marginal Zone Lymphoma in a Patient with Chronic Hepatitis C

    , , , and

    ABSTRACT

    Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) is a low-grade malignant lymphoma that appears frequently in the stomach, but other sites can also be involved: the intestinal tract, lungs, head, neck, skin, thyroid, breasts and liver. Recently, epidemiological evidences support the idea that there is an association between hepatitis C and B-cell non-Hodgkin lymphomas (that include MALT as a subtype). Primary non-Hodgkin lymphomas confined only to the liver are very rare (only 0.016% of all cases of all non-Hodgkin’s lymphomas) and MALT is not the most frequent type.
    We present the case of a male patient, age 62, known with chronic hepatitis C, previously relapser after a 72 week treatment with peg-interferon alfa and ribavirin that was diagnosed at three years after the relapse with multiple focal liver lesions. One of the tumors was surgically removed and the histological exam performed demonstrated an extranodal marginal zone lymphoma with small B-cell with plasmacytoid differentiation confined only to the liver. Direct acting antiviral (DAA) therapy was started, but the virologic clearance was not obtained by week 10, leading to a change of DAA regimen at week 12. The antiviral therapy was continued until week 24. Imaging showed an increase in number and size of the focal lesions until week 12. At week 12 chemo- and immune-therapy was started with bendamustine and rituximab. Afterwards the evolution was favorable, the patient being now in complete remission and with undetectable viral load.
    Keywords: Liver lymphoma, C hepatitis, extranodal marginal zone lymphoma, liver tumor

    Full text | PDF